Modality
Nanobody
MOA
CDK2i
Target
BCMA
Pathway
NF-κB
Schizophrenia
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
Sep 2018
→ Mar 2028
Phase 1Current
NCT06567865
325 pts·Schizophrenia
2018-09→2028-03·Recruiting
NCT07648210
2,301 pts·Schizophrenia
2022-02→TBD·Recruiting
2,626 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-172.0y awayInterim· Schizophrenia
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2028-03-17 · 2.0y away
Schizophrenia
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06567865 | Phase 1 | Schizophrenia | Recruiting | 325 | EFS |
| NCT07648210 | Phase 1 | Schizophrenia | Recruiting | 2301 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |